Your browser doesn't support javascript.
loading
Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial.
Torrens, Gabriel; van der Schalk, Thomas Ewout; Cortes-Lara, Sara; Timbermont, Leen; Del Barrio-Tofiño, Ester; Xavier, Basil Britto; Zamorano, Laura; Lammens, Christine; Ali, Omar; Ruzin, Alexey; Goossens, Herman; Kumar-Singh, Samir; Kluytmans, Jan; Paling, Fleur; MacLean, R Craig; Köhler, Thilo; López-Causapé, Carla; Malhotra-Kumar, Surbhi; Oliver, Antonio.
Afiliación
  • Torrens G; Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), CIBERINFEC, Palma de Mallorca, Spain.
  • van der Schalk TE; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
  • Cortes-Lara S; Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), CIBERINFEC, Palma de Mallorca, Spain.
  • Timbermont L; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
  • Del Barrio-Tofiño E; Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), CIBERINFEC, Palma de Mallorca, Spain.
  • Xavier BB; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
  • Zamorano L; Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), CIBERINFEC, Palma de Mallorca, Spain.
  • Lammens C; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
  • Ali O; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.
  • Ruzin A; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.
  • Goossens H; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
  • Kumar-Singh S; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
  • Kluytmans J; University Medical Centre Utrecht, Utrecht University, The Netherlands.
  • Paling F; University Medical Centre Utrecht, Utrecht University, The Netherlands.
  • MacLean RC; University of Oxford, Department of Zoology, Oxford, UK.
  • Köhler T; Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.
  • López-Causapé C; Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), CIBERINFEC, Palma de Mallorca, Spain.
  • Malhotra-Kumar S; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
  • Oliver A; Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), CIBERINFEC, Palma de Mallorca, Spain.
J Antimicrob Chemother ; 77(7): 1862-1872, 2022 06 29.
Article en En | MEDLINE | ID: mdl-35451008
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pseudomonas aeruginosa / Infecciones por Pseudomonas Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Antimicrob Chemother Año: 2022 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pseudomonas aeruginosa / Infecciones por Pseudomonas Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Antimicrob Chemother Año: 2022 Tipo del documento: Article País de afiliación: España